<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease is a multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> with features of <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It undergoes periods of spontaneous remission and relapse </plain></SENT>
<SENT sid="2" pm="."><plain>It often affects the skin, blood vessels, central <z:mp ids='MP_0008912'>nervous</z:mp> system, joints, gastrointestinal system, eyes, mucous membrane, and other systems, and it can cause substantial morbidity and mortality </plain></SENT>
<SENT sid="3" pm="."><plain>The etiology of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease remains unknown </plain></SENT>
<SENT sid="4" pm="."><plain>Current treatment of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease involves symptomatic relief with prevention of relapse </plain></SENT>
<SENT sid="5" pm="."><plain>We describe the treatment of a recalcitrant case of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease with infliximab and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The patient is a 40-year-old Korean woman with tender lesions on the lower extremities of 1.5 years' duration and intermittent oral and <z:e sem="disease" ids="C0151281" disease_type="Disease or Syndrome" abbrv="">genital ulcerations</z:e> that failed multiple conventional therapies </plain></SENT>
<SENT sid="7" pm="."><plain>The patient was placed on a trial of infliximab </plain></SENT>
<SENT sid="8" pm="."><plain>She reported resolution of the tender lower extremity lesions and the oral and <z:e sem="disease" ids="C0566951" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">vaginal ulcerations</z:e> shortly after the initiation of the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor agent </plain></SENT>
<SENT sid="9" pm="."><plain>The patient was symptom free for 2 years following the initiation of infliximab </plain></SENT>
<SENT sid="10" pm="."><plain>She subsequently reported mild breakthrough <z:hpo ids='HP_0000155'>oral ulcers</z:hpo> and <z:hpo ids='HP_0002829'>joint pain</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The treatment regimen was modified by adding <z:chebi fb="0" ids="44185">methotrexate</z:chebi> 7.5 mg weekly, <z:chebi fb="0" ids="8382">prednisone</z:chebi> 5 mg daily, and a shortened treatment interval of infliximab infusion that resulted in resolution of her symptoms </plain></SENT>
</text></document>